Your Shopping Cart Is Empty
| Report Code: A15646 | Oct 2022 | Pages: 143 | ||
| Tables: 75 | Charts: 48 |
| |
Pandemic disrupted the entire world and affected many industries.
Get detailed COVID-19 impact analysis on the Duchenne Muscular Dystrophy Market
Request Now !Duchenne Muscular Dystrophy Market (DMD) Insight (2022–2031)
The global Duchenne muscular dystrophy market size was valued at $1,301.44 Million in 2021, and is estimated to reach $2,073.91 Million by 2031, growing at a CAGR of 4.7% from 2022 to 2031.
A genetic condition known as Duchenne muscular dystrophy (DMD) is characterized by progressive muscle weakness and degradation as a result of changes to a protein called dystrophin that keeps muscle cells intact. DMD typically affects men, though it can occasionally affect women as well. Progressive weakening and loss (atrophy) of both skeletal and cardiac muscle are signs of DMD. Early warning indicators include difficulty in learning to talk and a delay in sitting, standing, or walking. Early childhood is typically when muscle weakness becomes apparent.
Cardiomyopathy or respiratory muscle weakness are the most common causes of death in people in the twenties, and cardiac and orthopedic issues are common. To avoid orthopedic problems, current treatment focuses on glucocorticoid therapy and physical therapy. Most patients start needing a wheelchair around the age of 10 to 12 and require assisted breathing around the age of 20. Most DMD patients with the best care pass away between the ages of 20 and 40 from cardiac and/or respiratory failure.
Duchenne muscular dystrophy is brought on by dystrophin gene mutations (DMD). The dystrophin gene contains 79 exons, and deletion mutations often affect multiple exons—which make up the majority of DMD alterations. Exon skipping is a DMD therapy that was created in response to the discovery of "reverent" fibers in the dystrophic muscle that can vary depending on the precise mutation. Exon skipping therapy is being introduced by a number of major market participants to treat Duchenne muscular dystrophy drives the market growth.
In addition, the rise in the incidence of the Duchenne muscular dystrophy (DMD) propels the market growth fuels the market growth. Furthermore, drug development has been quite active in recent years, with many research groups focused on the creation of novel medications for the treatment of DMD propels the Duchenne muscular dystrophy market growth.
However, the inflated cost of treatments for Duchenne muscular dystrophy is anticipated to limit the adoption of treatments during the forecast period. Conversely, rising need for better healthcare services, the healthcare sector is expanding significantly in both established and emerging economies. During the forecast period, the market for treatments is anticipated to benefit from rising government spending on the pharmaceutical and biotechnology sectors in developing countries, the development of healthcare infrastructure, and the rising demand for innovative treatments for Duchenne muscular dystrophy
COVID-19 Impact on Duchenne Muscular Dystrophy Market:
The COVID-19 pandemic is predicted to have a negative impact on the growth of the global Duchenne muscular dystrophy market. However, throughout the pandemic, despite the recommendations to maintain social distance, many individuals treated their illnesses via self-medication or other unconventional methods owing to their concern of contracting COVID during the lockdown.
Duchenne Muscular Dystrophy Segmentation
The Duchenne muscular dystrophy market is segmented on the basis of therapeutic area, distribution channel, and region. On the basis of therapeutic area, the market is categorized into molecular based therapies and steroid therapy. By distribution channel, it is classified into hospital pharmacies, drug store & retail pharmacies, and online Pharmacies. Region-wise, it is analyzed across North America, Europe, Asia-Pacific, Latin America, the Middle East, and Africa (LAMEA).
Segment Review
By therapeutic area, the market is segmented into molecular based therapies and steroid therapy. The molecular based therapies segment generated maximum revenue in 2021 and is expected to witness highest CAGR during the forecast period, owing to strong product pipeline and rise in product launch.
Depending on distribution channel, the market is divided into hospital pharmacies, drug store & retail pharmacies and online pharmacies. The hospital pharmacies segment dominated the market in 2021, owing to hospitals are primary source of treatment for patients. The drug store & retail pharmacies segment is expected to witness highest CAGR during the forecast period owing to it offers wide range of corticosteroids.
North America accounted for a majority of the global Duchenne muscular dystrophy drug market share in 2021 and is anticipated to remain dominant during the forecast period. This is attributed to technological advancements in Duchenne muscular dystrophy, presence of key and robust hospital infrastructure in the region. However, Asia-Pacific is anticipated to witness notable growth, owing rise in case of Duchenne muscular dystrophy, development of healthcare infrastructure and increase in investments projects in the region.
The major players profiled in the report are F Hoffmann-La Roche AG, FibroGen, Inc, GlaxoSmithKline plc, Italfarmaco S.p.A., Nippon Shinyaku Co., Ltd, Pfizer Inc., PTC Therapeutics, Santhera Pharmaceuticals Inc, Sarepta therapeutics and Wave life sciences ltd.
Key Benefits For Stakeholders
Duchenne Muscular Dystrophy Market Report Highlights
| Aspects | Details |
|---|---|
| By Therapeutic Class |
|
| By Region |
|
| By Key Market Players |
|
CHAPTER 1:INTRODUCTION
1.1.Report description
1.2.Key benefits for stakeholders
1.3.Key market segments
1.3.1.List of key players profile in the report
1.4.Research methodology
1.4.1.Primary research
1.4.2.Analyst tools and models
CHAPTER 2:EXECUTIVE SUMMARY
2.1.Key findings of the study
2.2.CXO perspective
CHAPTER 3:MARKET LANDSCAPE
3.1.Market definition and scope
3.2.Key findings
3.2.1.Top investment pockets
3.3.Porter’s five forces analysis
3.4.Market dynamics
3.4.1.Drivers
3.4.1.1.Launch of exon skipping technologies
3.4.1.2.Upsurge in the cases of Duchenne muscular dystrophy
3.4.1.3.Strong product pipeline
3.4.2.Restraint
3.4.2.1.High cost of treatment
3.4.3.Opportunity
3.4.3.1.Rise in healthcare expenditure
3.5.Impact analysis
3.6.Impact analysis of COVID-19 on the Duchenne muscular dystrophy market
CHAPTER 4:DUCHENNE MUSCULAR DYSTROPHY MARKET, BY THERAPEUTIC AREA
4.1.Overview
4.1.1.Market size and forecast
4.2.Molecular based therapy
4.2.1.Key market trends, growth factors, and opportunities
4.2.2.Market size and forecast
4.3.Steroid therapy
4.3.1.Key market trends, growth factors, and opportunities
4.3.2.Market size and forecast
CHAPTER 5:DUCHENNE MUSCULAR DYSTROPHY MARKET, BY DISTRIBUTION CHANNEL
5.1.Overview
5.1.1.Market size and forecast
5.2.Hospital pharmacies
5.2.1.Market size and forecast
5.3.Drug store and retail pharmacies
5.3.1.Market size and forecast
5.4.Online providers
5.4.1.Market size and forecast
CHAPTER 6:DUCHENNE MUSCULAR DYSTROPHY MARKET, BY REGION
6.1.Overview
6.1.1.Market size and forecast
6.2.North America
6.2.1.Key market trends, growth factors, and opportunities
6.2.2.North America Duchenne muscular dystrophy market, by therapeutic area
6.2.3.North America Duchenne muscular dystrophy market, by distribution channel
6.2.4.Market size and forecast, by country
6.3.Europe
6.3.1.Key market trends, growth factors, and opportunities
6.3.2.Europe Duchenne muscular dystrophy market, by therapeutic area
6.3.3.Europe Duchenne muscular dystrophy market, by distribution channel
6.3.4.Market size and forecast, by country
6.4.Asia-Pacific
6.4.1.Key market trends, growth factors, and opportunities
6.4.2.Asia-Pacific Duchenne muscular dystrophy market, by therapeutic area
6.4.3.Asia-Pacific Duchenne muscular dystrophy market, by distribution channel
6.4.4.Market size and forecast, by country
6.5.LAMEA
6.5.1.Key market trends, growth factors, and opportunities
6.5.2.LAMEA Duchenne muscular dystrophy market, by therapeutic area
6.5.3.LAMEA Duchenne muscular dystrophy market, by distribution channel
6.5.4.LAMEA Duchenne muscular dystrophy market, by country
CHAPTER 7:COMPETITION LANDSCAPE
7.1.Top winning strategies
7.2.Product mapping
7.3.Competitive dashboard
7.4.Competitive heatmap
7.5.Key developments
7.5.1.Product approval
7.5.2.Product innovation
7.5.3.Collaboration
7.5.4.Agreement
7.6.Top player positioning
CHAPTER 8:COMPANY PROFILES
8.1.F. HOFFMAN-LA ROCHE AG
8.1.1.Company overview
8.1.2.Key Executive
8.1.3.Company snapshot
8.1.4.Operating business segments
8.1.5.Product portfolio
8.1.6.Business performance
8.2.FIBROGEN, INC.
8.2.1.Company overview
8.2.2.Key Executives
8.2.3.Company snapshot
8.2.4.Operating business segments
8.2.5.Product portfolio
8.2.6.R&D expenditure .
8.2.7.Business performance
8.3.GALAXOSMITHKLINE PLC
8.3.1.Company overview
8.3.2.Key Executive
8.3.3.Company snapshot
8.3.4.Operating business segments
8.3.5.Product portfolio
8.3.6.R&D expenditure
8.3.7.Business performance
8.4.ITALFARMACO S.p.A.
8.4.1.Company overview
8.4.2.Company snapshot
8.4.3.Operating business segments
8.4.4.Product portfolio
8.5.NIPPON SHINYAKU CO.,LTD. (NS PHARMA)
8.5.1.Company overview
8.5.2.Key Executives
8.5.3.Company snapshot
8.5.4.Operating business segments
8.5.5.Product portfolio
8.5.6.R&D expenditure .
8.5.7.Business performance
8.6.PFIZER INC.
8.6.1.Company overview
8.6.2.Key Executives
8.6.3.Company snapshot
8.6.4.Operating business segments
8.6.5.Product portfolio
8.6.6.R&D expenditure .
8.6.7.Business performance
8.6.8.Key strategic moves and developments
8.7.PTC THERAPEUTICS, INC
8.7.1.Company overview
8.7.2.Key Executives
8.7.3.Company snapshot
8.7.4.Operating business segments
8.7.5.Product portfolio
8.7.6.R&D expenditure .
8.7.7.Business performance
8.7.8.Key strategic moves and developments
8.8.SANTHERA PHARMACEUTICALS, INC.
8.8.1.Company overview
8.8.2.Key Executives
8.8.3.Company snapshot
8.8.4.Operating business segments
8.8.5.Product portfolio
8.8.6.Business performance
8.8.7.Key strategic moves and developments
8.9.SAREPTA THERAPEUTICS
8.9.1.Company overview
8.9.2.Key Executives
8.9.3.Company snapshot
8.9.4.Operating business segments
8.9.5.Product portfolio
8.9.6.R&D expenditure .
8.9.7.Business performance
8.9.8.Key strategic moves and developments
8.10.WAVE LIFE SCIENCES LTD.
8.10.1.Company overview
8.10.2.Key Executives
8.10.3.Company snapshot
8.10.4.Operating business segments
8.10.5.Product portfolio
8.10.6.R&D expenditure .
8.10.7.Business performance
8.10.8.Key strategic moves and developments
LIST OF TABLES
TABLE 01.DUCHENNE MUSCULAR DYSTROPHY MARKET, BY THERAPEUTIC AREA, 2021-2031 ($MILLION)
TABLE 02.DUCHENNE MUSCULAR DYSTROPHY MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 03.DUCHENNE MUSCULAR DYSTROPHY MARKET, BY REGION, 2021-2031 ($MILLION)
TABLE 04.NORTH AMERICA DUCHENNE MUSCULAR DYSTROPHY MARKET, BY THERAPEUTIC AREA, 2021-2031 ($MILLION)
TABLE 05.NORTH AMERICA DUCHENNE MUSCULAR DYSTROPHY MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 06.NORTH AMERICA DUCHENNE MUSCULAR DYSTROPHY MARKET, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 07.EUROPE DUCHENNE MUSCULAR DYSTROPHY MARKET, BY THERAPEUTIC AREA, 2021-2031 ($MILLION)
TABLE 08.EUROPE DUCHENNE MUSCULAR DYSTROPHY MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION))
TABLE 09.EUROPE DUCHENNE MUSCULAR DYSTROPHY MARKET, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 10.ASIA-PACIFIC DUCHENNE MUSCULAR DYSTROPHY MARKET, BY THERAPEUTIC AREA, 2021-2031 ($MILLION)
TABLE 11.ASIA-PACIFIC DUCHENNE MUSCULAR DYSTROPHY MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 12.ASIA-PACIFIC DUCHENNE MUSCULAR DYSTROPHY MARKET, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 13.LAMEA DUCHENNE MUSCULAR DYSTROPHY MARKET, BY TTHERAPEUTIC AREA, 2021-2031 ($MILLION)
TABLE 14.LAMEA DUCHENNE MUSCULAR DYSTROPHY MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 15.LAMEA DUCHENNE MUSCULAR DYSTROPHY MARKET, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 16.ROCHE: KEY EXECUTIVE
TABLE 17.ROCHE: COMPANY SNAPSHOT
TABLE 18.ROCHE: BUSINESS UNITS
TABLE 19.ROCHE: PRODUCT PORTFOLIO
TABLE 20.ROCHE: NET SALES, 2019–2021
TABLE 21.FIBROGEN: KEY EXECUTIVES
TABLE 22.FIBROGEN: COMPANY SNAPSHOT
TABLE 23.FIBROGEN: BUSINESS UNITS
TABLE 24.FIBROGEN: PRODUCT PORTFOLIO
TABLE 25.FIBROGEN: R&D EXPENDITURE, 2019–2021
TABLE 26.FIBROGEN: NET SALES, 2019–2021
TABLE 27.GSK: KEY EXECUTIVE
TABLE 28.GSK: COMPANY SNAPSHOT
TABLE 29.GSK: OPERATING SEGMENT
TABLE 30.GSK: PRODUCT PORTFOLIO
TABLE 31.GSK: R&D EXPENDITURE, 2019–2021
TABLE 32.GSK: NET SALES, 2019–2021
TABLE 33.ITALFARMACO: COMPANY SNAPSHOT
TABLE 34.ITALFARMACO: OPERATING SEGMENTS
TABLE 35.ITALFARMACO: PRODUCT PORTFOLIO
TABLE 36.NS PHARMA: KEY EXECUTIVES
TABLE 37.NS PHARMA: COMPANY SNAPSHOT
TABLE 38.NS PHARMA: BUSINESS UNITS
TABLE 39.NS PHARMA: PRODUCT PORTFOLIO
TABLE 40.NS PHARMA: R&D EXPENDITURE, 2019–2021
TABLE 41.NS PHARMA: NET SALES, 2019–2021
TABLE 42.PFIZER: KEY EXECUTIVES
TABLE 43.PFIZER: COMPANY SNAPSHOT
TABLE 44.PFIZER: BUSINESS UNITS
TABLE 45.PFIZER: PRODUCT PORTFOLIO
TABLE 46.PFIZER: R&D EXPENDITURE, 2019–2021
TABLE 47.PFIZER: NET SALES, 2019–2021
TABLE 48.PFIZER: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 49.PTC: KEY EXECUTIVES
TABLE 50.PTC: COMPANY SNAPSHOT
TABLE 51.PTC: OERATING SEGMENT
TABLE 52.PTC: PRODUCT PORTFOLIO
TABLE 53.PTC: R&D EXPENDITURE, 2019–2021
TABLE 54.PTC: NET SALES, 2019–2021
TABLE 55.PTC: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 56.SANTHERA: KEY EXECUTIVES
TABLE 57.SANTHERA: COMPANY SNAPSHOT
TABLE 58.SANTHERA: OPERATING SEGMENTS
TABLE 59.SANTHERA: PRODUCT PORTFOLIO
TABLE 60.SANTHERA: NET SALES, 2019–2021
TABLE 61.SANTHERA: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 62.SAREPTA: KEY EXECUTIVES
TABLE 63.SAREPTA: COMPANY SNAPSHOT
TABLE 64.SAREPTA: BUSINESS UNITS
TABLE 65.SAREPTA: PRODUCT PORTFOLIO
TABLE 66.SAREPTA: R&D EXPENDITURE, 2019–2021
TABLE 67.SAREPTA: NET SALES, 2019–2021
TABLE 68.SAREPTA: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 69.WAVE LIFE: KEY EXECUTIVES
TABLE 70.WAVE LIFE: COMPANY SNAPSHOT
TABLE 71.WAVE LIFE: OPERATING SEGMENTS
TABLE 72.WAVE LIFE: PRODUCT PORTFOLIO
TABLE 73.WAVE LIFE: R&D EXPENDITURE, 2019–2021
TABLE 74.WAVE LIFE: NET SALES, 2019–2021
TABLE 75.WAVE LIFE: KEY STRATEGIC MOVES AND DEVELOPMENTS
LIST OF FIGURES
FIGURE 01.EXECUTIVE SUMMARY
FIGURE 02.EXECUTIVE SUMMARY
FIGURE 03.DUCHENNE MUSCULAR DYSTROPHY MARKET SEGMENTATION
FIGURE 04.TOP INVESTMENT POCKETS
FIGURE 05.MODERATE BARGAINING POWER OF SUPPLIERS
FIGURE 06.MODERATE BARGAINING POWER OF BUYERS
FIGURE 07.MODERATE THREAT OF SUBSTITUTES
FIGURE 08.HIGH THREAT OF NEW ENTRANTS
FIGURE 09.HIGH INTENSITY OF RIVALRY
FIGURE 10.IMPACT ANALYSIS
FIGURE 11.GLOBAL CHART, BY THERAPEUTIC AREA
FIGURE 12.MAKET SIZE BY MOLECULAR BASED THERAPIES
FIGURE 13.MAKET SIZE BY STEROID THERAPY
FIGURE 14.GLOBAL CHART, BY DISTRIBUTION CHANNEL
FIGURE 15.MAKET SIZE BY HOSPITAL PHARMACIES
FIGURE 16.MAKET SIZE BY DRUG STORE AND RETAIL PHARMACY
FIGURE 17.MAKET SIZE BY ONLINE PROVIDERS
FIGURE 18.GLOBAL CHARTS, BY REGION
FIGURE 19.TOP WINNING STRATEGIES, BY YEAR, 2019–2022*
FIGURE 20.TOP WINNING STRATEGIES, BY DEVELOPMENT, 2019-2022* (%)
FIGURE 21.TOP WINNING STRATEGIES, BY COMPANY, 2019–2022*
FIGURE 22.PRODUCT MAPPING OF TOP 10 KEY PLAYERS
FIGURE 23.COMPETITIVE DASHBOARD OF TOP 10 KEY PLAYERS
FIGURE 24.COMPETITIVE HEATMAP OF TOP 10 KEY PLAYERS
FIGURE 25.TOP PLAYER POSITIONING
FIGURE 26.ROCHE: NET SALES, 2019–2021 ($MILLION)
FIGURE 27.ROCHE: REVENUE SHARE BY SEGMENT, 2021 (%)
FIGURE 28.FIBROGEN: R&D EXPENDITURE, 2019–2021 ($MILLION)
FIGURE 29.FIBROGEN: NET SALES, 2019–2021 ($MILLION)
FIGURE 30.FIBROGEN: REVENUE SHARE BY REGION, 2021 (%)
FIGURE 31.GSK: R&D EXPENDITURE, 2019–2021 ($MILLION)
FIGURE 32.GSK: NET SALES, 2019–2021 ($MILLION)
FIGURE 33.GSK: REVENUE SHARE BY SEGMENT, 2021 (%)
FIGURE 34.GSK: REVENUE SHARE BY REGION, 2021 (%)
FIGURE 35.NS PHARMA: R&D EXPENDITURE, 2019–2021 ($MILLION)
FIGURE 36.NS PHARMA: NET SALES, 2019–2021 ($MILLION)
FIGURE 37.PFIZER: R&D EXPENDITURE, 2019–2021 ($MILLION)
FIGURE 38.PFIZER: NET SALES, 2019–2021 ($MILLION)
FIGURE 39.PFIZER: REVENUE SHARE BY SEGMENT, 2021 (%)
FIGURE 40.PFIZER: REVENUE SHARE BY REGION, 2021 (%)
FIGURE 41.PTC: R&D EXPENDITURE, 2019–2021 ($MILLION)
FIGURE 42.PTC: NET SALES, 2019–2021 ($MILLION)
FIGURE 43.PTC: REVENUE SHARE BY REGION, 2021 (%)
FIGURE 44.SANTHERA: NET SALES, 2019–2021 ($MILLION)
FIGURE 45.SAREPTA: R&D EXPENDITURE, 2019–2021 ($MILLION)
FIGURE 46.SAREPTA: NET SALES, 2019–2021 ($MILLION)
FIGURE 47.WAVE LIFE: R&D EXPENDITURE, 2019–2021 ($MILLION)
FIGURE 48.WAVE LIFE: NET SALES, 2019–2021 ($MILLION)
This section provides opinions of top level CXOs in the global Duchenne muscular dystrophy market. According to the insights of CXOs, leading companies in the market and development of advanced & reliable Duchenne muscular dystrophy therapeutics have led to extensive number of applications of this drug. Increase in prevalence of the disease and better healthcare services are expected to propel the Duchenne muscular dystrophy market.
Market growing at a steady rate in developed nations, Asia-Pacific and LAMEA are expected to offer high growth opportunities to key players in this market. According to the perspectives of CXOs of leading companies in the market, significant advancements in the Duchenne muscular dystrophy with increase in clinically backed research, growing investments, funds & grants, increasing incidence of disease, entry of new players, and strong product pipeline are projected to fuel the market growth.
A. The total market value of duchenne muscular dystrophy market is $1,301.44 million in 2021
A. The forecast period for duchenne muscular dystrophy market is 2022 to 2031
A. The market value of duchenne muscular dystrophy market in 2031 is $2,073.91 million.
A. The base year is 2021 in duchenne muscular dystrophy market
A. Top companies such as F Hoffmann-La Roche AG, FibroGen, Inc, GalaxoSmithKline plc, Italfarmaco S.p.A., Nippon Shinyaku Co., Ltd, Pfizer Inc., PTC Therapeutics, Santhera Pharmaceuticals Inc, Sarepta therapeutics, and Wave life sciences Ltd., held a high market position in 2021.
A. Molecular Therapies segment dominated the global market in 2021, and expected to continue this trend throughout the forecast period due to R & D for new exon skipping technologies for the treatment of duchenne muscular dystrophy.
A. Increase in prevalence of diseases, launch of molecular therapies and various technological advancements in duchenne muscular dystrophy is anticipated to drive the market in the forecast period.
A. North America is projected to account for a major share of the global duchenne muscular dystrophy market during the forecast period. U.S. dominated the North America duchenne muscular dystrophy market owing to approval and availability of drugs in the region.
Start reading instantly.
This Report and over 68,245+ more Reports, Available with Avenue Library. T&C*.
Enterprise
License/PDF
Library
Membership
*Taxes/Fees, if applicable will be added during checkout. All prices in USD
To ensure high-level data integrity, accurate analysis, and impeccable forecasts
For complete satisfaction
On-demand customization of scope of the report to exactly meet your needs
Targeted market view to provide pertinent information and save time of readers
Get insights on topics that are crucial for your business. Stay abreast of your interest areas.
Get Industry Data AlertsTo ensure high-level data integrity, accurate analysis, and impeccable forecasts
For complete satisfaction
On-demand customization of scope of the report to exactly meet your needs
Targeted market view to provide pertinent information and save time of readers
Contact Details
Need to talk to an expert? Book your free consultation and let our research experts help you with your needs/problems.
Global Report 
Regional Report
Country Report
Related Report